http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 12 Feb 2026 16:15:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. </p><p> To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F143071351&amp;esheet=54407351&amp;newsitemid=20260129139968&amp;lan=en-US&amp;anchor=webcast&amp;index=1&amp;md5=c831992ff8872ace28d6ac2b3f1ed4e8" shape="rect">webcast</a> of the conference call, as well as a http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html Thu, 29 Jan 2026 08:30:00 -0500 A.29655321 BIO BIO.B O.00005917 O.14972255 http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. </p><p> To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F143071351&amp;esheet=54407351&amp;newsitemid=20260129139968&amp;lan=en-US&amp;anchor=webcast&amp;index=1&amp;md5=c831992ff8872ace28d6ac2b3f1ed4e8" shape="rect">webcast</a> of the conference call, as well as a http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html Thu, 29 Jan 2026 08:30:00 -0500 A.29655321 BIO BIO.B O.00005917 O.14972255 http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. </p><p> To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F143071351&amp;esheet=54407351&amp;newsitemid=20260129139968&amp;lan=en-US&amp;anchor=webcast&amp;index=1&amp;md5=c831992ff8872ace28d6ac2b3f1ed4e8" shape="rect">webcast</a> of the conference call, as well as a http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html Thu, 29 Jan 2026 08:30:00 -0500 A.29655321 BIO BIO.B O.00005917 O.14972255 http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. </p><p> To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F143071351&amp;esheet=54407351&amp;newsitemid=20260129139968&amp;lan=en-US&amp;anchor=webcast&amp;index=1&amp;md5=c831992ff8872ace28d6ac2b3f1ed4e8" shape="rect">webcast</a> of the conference call, as well as a http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html Thu, 29 Jan 2026 08:30:00 -0500 A.29655321 BIO BIO.B O.00005917 O.14972255 http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. </p><p> To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F143071351&amp;esheet=54407351&amp;newsitemid=20260129139968&amp;lan=en-US&amp;anchor=webcast&amp;index=1&amp;md5=c831992ff8872ace28d6ac2b3f1ed4e8" shape="rect">webcast</a> of the conference call, as well as a http://www.streetinsider.com/Press+Releases/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html Thu, 29 Jan 2026 08:30:00 -0500 A.29655321 BIO BIO.B O.00005917 O.14972255 http://www.streetinsider.com/Business+Wire/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. </p><p> To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F143071351&amp;esheet=54407351&amp;newsitemid=20260129139968&amp;lan=en-US&amp;anchor=webcast&amp;index=1&amp;md5=c831992ff8872ace28d6ac2b3f1ed4e8" shape="rect">webcast</a> of the conference call, as well as a http://www.streetinsider.com/Business+Wire/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html Thu, 29 Jan 2026 08:30:00 -0500 A.29655321 BIO BIO.B O.00005917 O.14972255 http://www.streetinsider.com/Business+Wire/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. </p><p> To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F143071351&amp;esheet=54407351&amp;newsitemid=20260129139968&amp;lan=en-US&amp;anchor=webcast&amp;index=1&amp;md5=c831992ff8872ace28d6ac2b3f1ed4e8" shape="rect">webcast</a> of the conference call, as well as a http://www.streetinsider.com/Business+Wire/Bio-Rad+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results+on+Thursday%2C+February+12%2C+2026/25912755.html Thu, 29 Jan 2026 08:30:00 -0500 A.29655321 BIO BIO.B O.00005917 O.14972255